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Interventional Management of Malignant
Colorectal Obstruction: Use of Covered
and Uncovered Stents
Objective: We wanted to evaluate usefulness of uncovered stent in compari-
son with covered stent for the palliative treatment of malignant colorectal obstruc-
tion.
Materials and Methods: Covered (n = 52, type 1 and type 2) and uncovered (n
= 22, type 3) stents were placed in 74 patients with malignant colorectal obstruc-
tion. Stent insertion was performed for palliative treatment in 37 patients (covered
stent: n = 23 and uncovered stent: n = 14). In the palliative group, the data on the
success of the procedure, the stent patency and the complications between the
two groups (covered versus uncovered stents) were compared. 
Results: The technical success rate was 89% (33/37). Symptomatic improve-
ment was achieved in 86% (18/21) of the covered stent group and in 92% (11/12)
of the uncovered stent group patients. The period of follow-up ranged from three
to 319 days (mean period: 116 85 days). The mean period of stent patency was
157 33 days in the covered stent group and 165 25 days in the uncovered
stent group. In the covered stent group, stent migration (n = 11), stent fracture (n
= 2) and poor expansion of the stent (n = 2) were noted. In the uncovered stent
group, tumor ingrowth into the stents (n = 3) was noted. 
Conclusion: Self-expanding metallic stents are effective for relieving malignant
colorectal obstruction. The rate of complications is lower in the uncovered stent
group than in the covered stent group. 
alliative treatment of malignant colorectal obstruction should be consid-
ered for the patients suffering with primary disseminated or recurrent
cancer. The treatment options depend on the patient’s condition, the site
of obstruction, the extent of disease and the life expectancy. In many cases and partic-
ularly for palliative surgery, creation of colostomy is inevitable, and it may result in
increased patient discomfort (1). Various non-surgical treatment procedures such as
balloon dilatation, laser photoablation and electrocoagulation have been performed
(2 4). However, their effectiveness is limited by the need for repeated treatments that
are time-consuming and they increase the patient’s discomfort and the medical costs,
and these repeated treatments are associated with complications.
Metallic stents have been used for the palliative treatment of malignant obstruction
of the biliary and gastrointestinal tracts (5 7). Application of metallic stents for the
treatment of acute malignant colonic obstruction was first reported by Dohmoto in
1991, and it has become a promising treatment option (8), although the number of
reported cases is only 600 throughout the world (9, 10). According to the reports,
stent implantation is the best final palliative treatment for some cases that are in an
advanced stage of disease. Yet the patients who undergo palliative treatment develop
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Pnew colonic obstructions or tumor ingrowth into the stent,
and additional complications include stent migration, pain,
bleeding and bowel perforation (11 21). To prevent
tumor ingrowth and to treat fistulae, a covering has been
applied to bare stents, but the stent migration problem still
persists, and problems with the newly introduced system
still persist (13, 21). To date, there has been no report that
has compared the use of covered stents and the use of the
uncovered stents in patients with malignant colorectal
obstruction.
The purpose of this study was to evaluate the usefulness
of uncovered stent in comparison with covered stent for




From June 1997 to February 2002, 74 patients (35 men
and 39 women, age range: 32 85 years, mean age: 60
years) with colorectal obstruction caused by colorectal
carcinoma underwent self-expandable metallic stent
insertion for decompression of acute colonic obstruction. In
37 patients, the stents were placed for presurgical
decompression of obstruction that was caused by primary
colonic adenocarcinoma. In another group of 37 patients,
colonic stents were placed for palliative relief. The
preoperative decompression group of patients was
excluded from our study.
The diagnosis of colonic obstruction was initially
established on the basis of the patients’ clinical history,
rectal examinations and the plain radiography. Computed
tomography (CT) and barium-enema or water-soluble
contrast enema examinations or both were then performed
to help confirm the presence of an obstructive mass and to
determine the precise location of the lesion. The
histopathologic diagnosis was established by analyzing the
results of endoscopic biopsy that was performed previously
or at the time of the stent insertion. The sites of obstruction
were the sigmoid colon in nine patients, the rectosigmoid
colon in 24 patients and the descending colon in four
patients. The causes of palliation were metastasis (n = 17),
seeding (n = 11), local tumor recurrences (n = 8) and rectal
cancer with bladder invasion and fistula (n = 1).
Stents
We used three types of commercially manufactured
stents (CHOO stent; MITech, Seoul, Korea) that were
designed for application in the gastrointestinal tract (Fig.
1). The original stent was a flexible covered metallic stent
that had three parts: the proximal part, the body (middle
portion of the stent) and the distal part. The body of the
stent was constructed of 0.4-mm stainless steel wire in a
cylindrical zigzag configuration of 15 bends; it was 22 mm
in diameter and 10 mm long. The proximal and distal parts
were 8 mm wider in diameter than the body of the stent,
and the length was 2 cm long; these parts were connected
at a right angle to the body by three metallic struts. The
proximal and distal parts were constructed of 0.5-mm
diameter stainless steel wire with the same mesh. The stent
mesh was covered with polyurethane to inhibit growth of
the tumor into the stent. There were 3 mm gaps made of
only polyurethane that were located between the metallic
stent of the body to maintain its longitudinal flexibility.
The thickness of the polyurethane coverage at the gap
portion was 100 200  m at the early stage of the study,
and it was increased to 300 500  m during the later
period. Two types of flexible covered stents were
Choi et al.
58 Korean J Radiol 8(1), February 2007
AB
Fig. 1. Type 1 (A), type 2 (B) and type 3 (C) stents. To prevention
migration, two-thirds of the proximal part of the type 2 stent is not
covered (arrowheads). 
Cconstructed. Type 1 stents were fully covered with
polyurethane. Type 2 stents were not covered in two-
thirds of the proximal part so as to prevent their migration.
The type 3 stent was an uncovered stent that was made
of 0.17 mm diameter nitinol wires. The wires were knitted
in a closed zigzag configuration, joined by plenty of bends,
and they were wound cylindrically with looped ends. The
stent was from 22 mm to 28 mm in diameter. A gold wire
was attached to both ends of the stent to solve the problem
of the radiopacity of the nitinol wire. The length of the
stent varied from 6 to 16 cm. 
The covered stent was mounted on a polytetrafluoroeth-
ylene introduction tube that was 6 mm at the outer
diameter. The outer diameter of the introducing tube of
the uncovered stent was 10.5 Fr. The pusher catheter was
made of polyurethane. The delivery system was composed
of a guiding tip, a guiding tube, an introduction tube, a
pusher catheter and the compressed stent. The patients
were divided into three groups: Type 1 stents (n = 10)
were used between June 1997 and December 1997, type 2
stents (n = 42) were used between January 1998 and
February 2000 and type 3 stents (n = 22) were used
between August 2000 and February 2002.
Stent Placement
The details of the procedure have been described
previously (21). For sedation, 1 2 mg of midazolam
(Versed; Roche Laboratories, Nutley, NJ) was adminis-
tered intravenously before starting the stenting procedure.
Under fluoroscopic guidance, a 145-cm-long, 0.038-inch-
diameter hydrophilic guide wire (Terumo, Tokyo, Japan)
was advanced across the stricture. After an angiographic
catheter was advanced above the stricture over the guide
wire, the guide wire was removed and a water-soluble
contrast material (Telebrix, Guerbet, France) was injected
to define the length of the obstruction. The length of
obstruction was measured by withdrawing the guide wire
from the proximal portion of the obstruction to its distal
port. A 0.038-inch-diameter guide wire (Amplatz
Superstiff; Meditech/Boston Scientific, Watertown, MA)
was then introduced. After an adequate study of the
location and the length of the stricture, the delivery system
of the stent was coated with lubricating jelly and advanced
over the guide wire under fluoroscopic guidance. A stent at
least 4 cm longer than the stricture segment was placed so
that the stricture was fully covered. The pusher catheter
was then held in place while the introducing tube was
withdrawn. This maneuver released the stent and allowed
it to expand within the stricture. After the deployment of
the stent, the delivery system and the guide wire were
removed, and a water-soluble contrast enema was
performed to assess the position and patency of the stent
and to evaluate for any complications that might have
occurred during the procedure. In lesions that failed to pass
the guide wire with fluoroscopic guidance, we tried to pass
the obstructed lesion under combined fluoroscopic and
endoscopic guidance. 
Follow-up
After the stent placement, a plain radiograph of the
abdomen was obtained at 24, 48, and 72 hours, and we
evaluated the position of the stent and the relief of the
colonic obstruction. After the colonic obstruction was
relieved, a barium enema was performed to exclude the
possibility of synchronous carcinoma. An additional
barium enema study was performed when the patients
showed symptoms of colonic obstruction or stent
migration. The observation parameters of the follow-up
examination included the symptoms, the stent patency and
the complications.
Technical success was defined as stent insertion at the
lesion site without immediate complications. Clinical
success was defined as relief of the bowel obstruction
according to the clinical and radiological findings within 24
hours after the stent placement. The period of patency was
calculated from the time of stent placement to the
recurrence of symptoms of obstruction in the clinically
successful cases. The rates of technical success, clinical
success and complications were analyzed using the chi-
square test, and the Kaplan-Meier method was used to
analyze the mean period of patency and the survival time
between the covered and the uncovered stents.
RESULTS
The overall technical success rate of stent placement was
89% (33/37). The procedure was performed under fluoro-
scopic guidance alone in 32 cases; combined guidance was
required in five patients. Despite the combined fluoro-
scopic and endoscopic guidance, we failed to pass the guide
wire over the obstructive segment in three cases. In one
case, the delivery system could not get over a tortuous
rectosigmoid region after the stiff guide wire had crossed
the obstruction. Emergency laparotomy operations were
performed in both of these two patients, and colostomy or
Hartmann’s procedure was completed.
In 88% (29/33) of the patients, the clinical manifesta-
tions and radiographic findings of the bowel obstruction
resolved within 24 hours after stent placement. In patients
with resctosigmoid seeding by advanced gastric carcinoma
(n = 2), cervical cancer (n = 1) and ovarian cancer (n = 1),
their bowel obstruction was relieved two or three days
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Complications were noted in 15 patients. The stent
migration rate was 33% (11/33) and the duration between
stent placement and the migration was 3-72 days (mean:
14 days). Stent migration developed in all the cases (4/4)
with type 1 stent and in seven cases with type 2 stent.
Stent migration developed within a week in one patient
and between one and three weeks in the three patients
with the type 1 stent. For the type 2 stent, migration was
noted within one week in five patients and after a week in
two patients.
Stent migration was not noted in the type 3 stent
patients. The migration rate was significantly higher in the
covered stent group than in the uncovered stent group of
patients (p = 0.009). In three of the cases with migrated
stent, the stent was expelled out of the anus. For migration
of the type 1 stent, a second stent was inserted to two
patients, colostomy was performed to one and no further
treatment was given to one patient. For migration of the
type 2 stent, a second stent was inserted for two patients,
colostomy was performed for two and no further
treatment was given to three patients.
For the type 2 stent, stent fracture was noted in two
cases, which occurred 14 days in one and 180 days in the
other after stent insertion (Fig. 2). Stent fracture was noted
incidentally on the regular follow-up radiography examina-
tions without any specific symptom. Insertion of a second
stent was performed in one patient, and surgical operation
with colostomy was performed in another patient.
For two cases where the stent did not expand
adequately, the patients revealed tumor seeding by
cervical cancer and ovarian cancer, respectively (Fig. 3).
Insertion of a second stent was performed in one patient,
and surgical operation with colostomy was performed in
the other patient.
Tumor ingrowth, which was confirmed by CT,
developed in three patients with the type 3 stent, but
further bowel obstruction was not noted before death (Fig.
4). The tumor ingrowth rate was significantly higher in the
uncovered stent group (p = 0.014). In the uncovered stent
group, one patient developed symptoms of reobstruction
35 days after the stent placement. The cause of the
symptoms was fecal impaction, and the symptoms
improved with administering a bowel enema. There was
no case of tumor overgrowth in this study.
Minor complication, such as abdominal pain, mild
bleeding and tenesmus, improved with conservative
treatment. 
The period of the follow-up was 3 319 days (mean: 116
85 days). The mean period of patency was 157 33 days
with the covered stent and 165 25 days with the
uncovered stent: the difference was statistically insignifi-
cant (p = 0.481). The mean survival time was 142 days
(range: 55 319 days).
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Fig. 2. Stent fracture of the type 2 stent in a 64-year-old patient.
180 days after stent insertion, the stent broke between the
proximal end and the body (arrows).
Fig. 3. Inadequate expansion of the type 2 stent in a 60-year-old
patient. Seven days after insertion, inadequate expansion of the
stent was noted.DISCUSSION
Patients with unresectable primary or recurrent
malignant colonic obstruction at presentation represent a
great medical and ethical dilemma (22, 23). They have a
limited life expectancy and they may benefit from a safe,
effective and non-surgical alternative treatment to relieve
their obstructive symptoms. The primary goal of the non-
surgical approach to the treatment of acute colonic
obstruction is to eliminate the need of performing urgent
surgical treatment on the inadequately prepared colon in
an insufficiently stabilized patient.
Treatment of acute colorectal obstruction with using
metallic stents is a recent advance that has been mainly
used for preoperative decompression (12, 20, 24). In
recent years, some authors have reported favorable results
for non-surgical relief of acute malignant colonic obstruc-
tion by placing an uncovered, self-expandable metallic
stent (11 13, 16 19). The technical and clinical success
rates of our study are comparable to other series, which
varied between 80% and 100% (11 21, 24 28). The site
of the lesion influences the technical success rate, with
rectosigmoid lesions being easier to treat than transverse
colon lesions. Among our cases, technical failure within the
descending colon occurred in two cases, within the sigmoid
colon in one case and within the rectosigmoid colon in one
case. 
Generally speaking, the covered stents have the
advantage of resisting tumor ingrowth, but they tend to be
less stable and more rigid. They also require larger delivery
systems; thus, it is more difficult to deploy them at distant
locations through a tortuous path of delivery (13, 21). Using
a covered stent is favorable because these stents have
potential advantages in respect of the longer stent patency,
the prevention of tumor ingrowth during palliative
treatment and they exclude tumor-induced fistulae (13, 21).
Uncovered stents are more flexible, and at least one variety
of them can be passed through the working channel of the
endoscope. For the purpose of immediate decompression
and scheduled surgery, an uncovered stent of a correct
length is the optimal choice. However, when used for the
long-term palliative treatment of malignant obstruction,
they are subject to tumor ingrowth and the resultant
obstruction. Rey et al. have reported that early occlusion of
uncovered stents occurred in all their eleven patients during
45 91 days of follow-up (14). Because stents made specifi-
cally for entral use were not available until 1998, they used
stents smaller in the diameter (10 20 mm) than those we
are currently using, and that type of stent may be the
reason for the early occlusion of the stents. A stent has
recently been marketed specifically for use in the colon.
According to a recent report on using uncovered stents for
palliation of malignant colorectal obstruction, reobstruction
due to tumor ingrowing or overgrowing occurred in 7.6
months (range: 4 10 months), and the mean survival time
was 5.3 months (16). Another research reported that in
patients who had uncovered stents used for palliation of
unresectable secondary colorectal carcinoma, the patency
of the stent was longer than the patients’ survival time (17).
Although three cases of tumor ingrowths were observed on
CT examinations in our study, there were no intestinal
obstructions during the patients’ survival in the uncovered
stent group. Therefore, coverage did not have a clinically
significant influence in the cases treated for palliative relief
of bowel obstruction. According to the results of our study,
the uncovered stents showed a lower complication rate
with no difference in the patency rate in the palliative
group. Therefore, we now prefer to use the bare stent
because of its comparably high stent patency, the lower
migration rate and the stable stent mesh that doesn’t
fracture. 
Complications of colorectal stenting include perforation,
migration, pain, tenesmus, bleeding, tumor ingrowth or
overgrowth and stent fracture. The complication rate has
been reported to range from 14% to 42% (11, 12, 21, 24
26). In various studies, migration has been reported to
happen in 4% to 23% of the cases (20, 27). In our study,
all the migrations, except one, occurred within 30 days.
The established causes of stent migration were the shrink-
age of tumors that occurred as a result of adjuvant
chemotherapy (12), a weak radial expansive force (14) and
a covered stent (21). We think that the principal
mechanism of stent migration was associated with the
unstable attachment of the stent to the intestinal wall due
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Fig. 4. Tumor ingrowth of the type 3 stent in a 65-year-old patient.
135 days after stent insertion, tumor ingrowth on the CT scan
was seen (arrows). No symptomatic bowel obstruction was noted
until the patient’s death.to the stent coverage and peristaltic movements of the
bowel. After we designed a new uncovered nitinol stent,
no cases of stent migration were noted.
Stent fracture and inadequate expansion were noted in
only a covered stent in our study. This was probably
caused by the characteristics of the stent used in this study.
In the manufactured covered stents, the stent mesh was not
an interconnected one body, but it consisted of segment
parts connected by the covering of polyurethane, so the
stent could be easily fractured if the covering material was
damaged. This could also be caused by the weak radial
force in the structure of the stent. More frequent fractured
stent struts in the covered stent were considered to be the
result of unbalanced mechanical stress due to the covering
material and a big stent burden. 
Perforation of the bowel is the most dangerous complica-
tion because the subsequent fecal peritonitis can be fatal.
Colonic perforation following stent deployment is a well
recognized problem, and it is more common when balloon
dilatation is used to predilate the stricture (9). None of the
patients had bowel perforation in this series.
This study has several drawbacks. As the stents were
applied differently during a specific period and they were
not randomized, this study could not achieve proper
comparative analysis, so it has a statistical limitation. A
prospective randomized study is needed to overcome this
limitation. 
In conclusion, favorable technical and clinical results
were obtained for palliative treatment with stent insertion
for treating malignant colorectal obstruction.
Complications developed less frequently with the
uncovered stent than with the covered stent, and stent
migration especially became less frequent, and the purpose
of palliation seems to have been achieved. 
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